Histiocytic Sarcoma: A case of a 52-year-old female with
two synchronous primary malignancies at presentation
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Case Report

A 52-year-old female with a past medical history of chronic
obstructive pulmonary disease, coronary artery disease, and
an 80-pack-year smoking history presented to the emergency
room with complaints of right upper extremity weakness and
imbalance while walking for the previous two days. She stated
that the onset was abrupt and progressively worsening to the
point where she could no longer lift her right upper extremity
against gravity. She maintained the ability to move her hand
and grasp, but admitted to decreased strength and decreased
dexterity of her right hand. She denied changes in vision. She
also denied having bowel or bladder incontinence. She has no
known allergies and her only medications included occasional
benzodiazepines for anxiety and acetaminophen/oxycodone
for low back pain. Her family history was notable only for lung
cancer, which was the cause of death of her mother.
On admission, the patient’s vital signs were stable. She was
afebrile, alert, and oriented to person, place, and time. Her
physical exam was notable for profoundly reduced strength rated
at 1/5 in her proximal right upper extremity. Her distal forearm

Figure 2. Axial view of T1 weighted MRI brain demonstrating
left cerebral enhancing mass with surrounding edema
and hand were also reduced at 3/5 intensity. Her sensation
in her right upper extremity was intact and symmetrical. All
reflexes in her upper and lower extremities were 1+.
A CT scan of her head revealed a large enhancing mass in the
left parietal region. The patient was given levetiracetam 500 mg
twice daily for seizure prophylaxis and dexamethasone 4 mg
every 6 hours to reduce inflammation and edema surrounding
the brain mass. A CT scan of the chest, abdomen, and pelvis was
obtained for further workup and staging prior to surgery. This
study revealed cavitating lung masses in the anterior left upper
lobe and posterior right lobe, likely representing synchronous
primary lung malignancies.

Figure 1. T1 weighted Brain MRI at the time of admission
demonstrates a 1.6 x 1.5 x 1.7 cm solid enhancing mass
centered on the left corona radiata with extensive surrounding
vasogenic edema. T1 weighted Brain MRI at the time of
admission demonstrates a 1.6 x 1.5 x 1.7 cm solid enhancing
mass centered on the left corona radiata with extensive
surrounding vasogenic edema.

An MRI of the brain (Figures 1–2) on the same date revealed
a 1.6 x 1.5 x 1.7 cm mass in the left centrum semiovale. After
discussion with radiologists reading the image, the findings
on MRI were concerning for primary CNS lymphoma and
thought to be atypical findings for a metastatic brain lesion.
A bronchoscopy performed the following day found an
endobronchial lesion nearly occluding the left upper lobe, and
biopsy yielded a diagnosis of squamous cell carcinoma.
Given the fact that the read on the MRI was inconsistent with
metastatic disease from a possible lung origin and was more
consistent with a primary CNS lymphoma, we felt it was
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identified dense collections of histiocytes present within reactive
brain tissue. Many of the histiocytes were atypical in appearance
and stained CD68 and CD163 positive, which is consistent with
a diagnosis of histiocytic sarcoma.
The patient initially responded well to steroids and regained
most of the function of her upper and lower extremity and was
discharged from the hospital after the initial workup. However,
she was readmitted in less than one week with progressively
worsening weakness and gait abnormalities and was found to
have a slightly larger mass on imaging studies (Figure 5). Because
of her severe neurological impairment, she was discharged to
inpatient rehabilitation. Due to her functional status, she was
not a candidate for chemotherapy, and she expired from severe
hemoptysis that was likely secondary to erosion of her lung
cancer through a pulmonary artery.

Discussion

Figure 3. Light microscopy of brain lesion biopsy shows
dense collection of histiocytes, many of which are atypical in
appearance. (10x magnification, H and E stain)

The case presented above is noteworthy not only for the unusual
presentation of synchronous primary neoplasms, but also for
the diagnosis of a rare form of non-Hodgkin's lymphoma,
histiocytic sarcoma (HS), which we believe to be a primary CNS
histiocytic sarcoma. Histiocytic sarcoma is a rare malignancy
that makes up less than 1% of all diagnosed non-Hodgkin’s
lymphoma and has mostly been reported only in small series
of case reports. 1 It is a malignancy of hematopoeitic cells
resembling histiocytes but can be confused with similar looking
T- and B-cell neoplasms. An extensive array of antibodies
must be evaluated to differentiate HS from Langerhans Cell
Sarcoma, diffuse large B-cell lymphoma, peripheral T-cell

Figure 4. Atypical histiocyte seen at high power. (100x
magnification, H and E stain)
necessary to proceed with a biopsy of the brain lesion before
initiating treatment for lung cancer. During the course of
the hospital stay, the patient was fortunate to have improved
function of her right arm and her gait returned to normal. She
was discharged with a steroid taper.
The final brain biopsy (Figures 3–4) results were obtained after
discharge and confirmed the diagnosis of a second separate
malignant process involving the brain. Evaluation of the biopsy
in consultation with the pathology department at the NIH
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Figure 5. Axial view of T1 weighted MRI of the brain 24 days
after admission demonstrates a progressively enlarging mass
(measuring 2.0cm x 1.6cm x 1.9cm) and worsening surrounding
edema. This tumor progression is consistent with an aggressive
nature of histiocytic sarcoma.

lymphoma, acute lymphocytic lymphoma (ALL), metastatic
undifferentiated carcinoma, and melanoma.1,2,3 Unlike other
lymphomas, HS usually presents with extranodal involvement.
About one-third of cases present within lymph nodes, and
two-thirds are extranodal at presentation.2 Of the extranodal
cases, about half present with skin lesions, and the other half
with various sites of involvement including the intestinal tract,
and rarely the central nervous system (CNS).2,4,5 HS is usually
an aggressive malignancy that presents with constitutional
symptoms such as fever and weight loss and symptoms related
to organ involvement such as pancytopenia, bowel obstruction,
rash, and subcutaneous nodules.2 When diagnosed, HS is most
often at an advanced clinical stage with high mortality and
little response to chemotherapy. Patients with primary CNS
histiocytic sarcoma described in case reports have expired
within 3 to 8 months of diagnosis from various complications.3,4
Our patient presented with only extranodal involvement of
the CNS, suffered from severe neurological impairment and
survived for one month after her diagnosis was made. Although
she likely died from complications of lung cancer, her functional
status was progressively worsening due to the increasing size of
the histiocytic sarcoma in her brain.
Due to the rarity of the disease and lack of studies to validate
diagnostic criteria, HS is difficult to diagnose. Several markers
used to help diagnose HS are histiocyte-associated antigens, such
as CD68, lysozyme, CD11c, and CD14.2,4 Diagnosis also requires
a lack of expression of other known cell lineages such as B-cells,
T-cells, myeloid cells, follicular dendritic cells, and CD30.4 More
recently, CD163 has been identified as an important factor for
the diagnosis of HS. CD163 is a hemoglobin scavenger receptor
and its expression is limited to neoplasms of monocytic/
histiocytic derivation. It is more specific than other markers
such as CD68. Cao et al. published in 2007 a case of primary
CNS HS and confirmed the importance of distinguishing CD68
and CD163 positive tumors as HS versus other malignancies.6
Before CD163 was identified, HS was more difficult to diagnose
and perhaps overdiagnosed.1 There are several case reports
identifying histiocytic sarcoma as a primary CNS tumor 4,5,
but these reports came before identification of CD163 as an
important factor for diagnosis. The patient presented in the case
above had a primary CNS malignancy that stained positive for
both histiocyte-associated antigen CD68 and histiocyte-specific
CD163 receptor.

Cao et al. also commented that, considering their findings of
mild cytologic atypia and a profound inflammatory componont,
their initial impression was one of a chronic inflammatory
process. 6 Prominent inflammatory infiltrates have been
described in all five of the previously reportedpublished cases
in the literature of primary CNS HS. A chronic inflammatory
process and was on our differential diagnosis in the beginning
as well.6 Interestingly, due to the rarity of the final diagnosis,
which required numerous histochemical stains and second
opinions from pathology departments at other institutions,
the final diagnosis of histiocytic sarcoma was not obtained for
several weeks following the biopsy. During this time, other
possible etiologies for the brain lesion, including infectious
diseases, were ruled outconsidered and eventually eliminated.
There radiographic appearance of CNS lesions is the key to their
differentiation. Features typical of metastatic disease include
multiple lesions, spherical shape, well demarcated borders,
and their location at the gray matter-white matter junction.7
The lesion in this case, although well-circumscribed, was felt
to be uncharacteristic of metastatic disease due to the depth of
location and lack of multiple CNS lesions. Ultimately, it was
this radiographic appearance that lead us to pursue further
pathologic diagnosis.

References
1.

Vos JA, Abbondanzo SL, Barekman CL, et al. Histiocytic sarcoma: a study of
five cases including the histiocyte marker CD163. Modern Pathology 2005;18,
693-704.

2.

World Health Organization Classification of Tumors: Pathology and Genetics
of Tumours of Haematopoietic and Lymphoid Tissue. Lyon France IARC Press;
2001:278-279.

3.

Yu L, Yang SJ. A Case of Primary Histiocytic Sarcoma arising from the Thyroid
Gland. Pathology and Oncologic Research 2009; 1219-4956.

4.

Cheuk W, Walford N, Lou J, et al. Primary Histiocytic Lymphoma of the Central
Nervous System. The American Journal of Surgical Pathology 2001;25: 1372-1379

5.

Sun W, Nordberg M, Fowler M. Histiocytic Sarcoma Involving the Central
Nervous System. Ther American Journal of Surgical Pathology 2003;27: 258-265.

6.

Cao M, Eshoa C, Schultz C, et al. Primary Central Nervous System Histiocytic
Sarcoma with Relapse to Mediastinum. Archives of Pathology Lab Medicine
2007;131: 301-305.

7.

Sagar Stephen M, Israel Mark A, “Chapter 374. Primary and Metastatic Tumors
of the Nervous System” (Chapter). Fauci AS, Braunwald E, Kasper DL, Hauser
SL, Longo DL, Jameson JL, Loscalzo J: Harrison’s Principles of Internal Medicine,
17e: http://www.accessmedicine.com/content.aspx?aID=2906281. Accessed
October 27, 2009.

33

